Lixte Biotechnology Holdings, INC 10-Q quarterly reports

Nomad Power Solutions, Inc. (formerly Lixte Biotechnology Holdings, Inc.) reported its Q2 2026 results, highlighting a strategic shift into AI energy infrastructure and the completion of its merger with NOMAD Transportable Power Systems, Inc.

Lixte Biotechnology Holdings, Inc. reported a net loss of $1.99 million for Q1 2026, with significant increases in R&D and G&A expenses, while cash reserves decreased.

Lixte Biotechnology Holdings, Inc. reports significant capital raises and Nasdaq compliance, despite increased net losses and a clinical trial pause due to serious adverse events.

Lixte Biotechnology Holdings, Inc. reported reduced losses and successful capital raises, securing its Nasdaq listing, but faces a clinical trial hold due to serious adverse events.

Lixte Biotechnology Holdings reports a net loss for Q1 2025 and highlights its ongoing clinical trials and the necessity for additional capital to continue operations.

Lixte Biotechnology reported a net loss of $986,030 for Q3 2024 and is facing substantial doubt about its ability to continue as a going concern, along with Nasdaq listing compliance challenges.

Lixte Biotechnology Holdings reported a net loss of $1.98 million for the first six months of 2024, as the company continues to advance its clinical programs.

Lixte Biotechnology Holdings reported a net loss of $971,322 for the first quarter of 2024 and highlighted substantial doubt about its ability to continue as a going concern.